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Abstract
Background: The significant reduction of angiographic restenosis rates in the ISAR-SWEET study
(intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate
elevated thrombotic risk in diabetes) raises the question of whether abciximab acts on clopidogrel-
independent mechanisms in suppressing neointimal hyperplasia. The current study investigates the
direct effect of abciximab on ICAM-1 expression, migration and proliferation.
Methods: ICAM-1: Part I of the study investigates in cytoflow studies the effect of abciximab
(0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on TNF-α induced expression of intercellular
adhesion molecule 1 (ICAM-1). Migration: Part II of the study explored the effect of abciximab
(0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on migration of HCMSMC over a period of 24 h.
Proliferation: Part III of the study investigated the effect of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0,
and 20.0 μg/ml) on proliferation of HUVEC, HCAEC, and HCMSMC after an incubation period of
5 days.
Results: ICAM-1: In human venous endothelial cells (HUVEC), human coronary endothelial cells
(HCAEC) and human coronary medial smooth muscle cells (HCMSMC) no inhibitory or
stimulatory effect on expression of ICAM-1 was detected. Migration: After incubation of HCMSMC
with abciximab in concentrations of 0.0002 – 2 μg/ml a stimulatory effect on cell migration was
detected, statistical significance was achieved after incubation with 0.002 μg/ml (p < 0.05), 0.002
μg/ml (p < 0.001), and 0.2 μg/ml (p < 0.05). Proliferation: Small but statistically significant
antiproliferative effects of abciximab were detected after incubation of HUVEC (0.02 and 2.0 μg/
ml; p = 0.01 and p < 0.01), HCAEC (2.0 and 20.0 μg/ml; p < 0.05 and p < 0,01), and HCMSMC (2.0
and 20.0 μg/ml; p < 0.05 and p < 0.05). The significant inhibition (SI) of cell proliferation found in
HCAEC and HCMSMC was achieved with drug concentrations more than 10 times beyond the
maximal plasma level (MPL), resulting in a SI/MPL-ratio > 1.
Conclusion: Thus, the anti-restenotic effects of systemically administered abciximab reported in
the ISAR-SWEET-study were not caused by a direct inhibitory effect on ICAM-1 expression,
migration or proliferation.
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Background
The observations that abciximab was associated with a
reduction in angiographic restenosis rates in the ISAR-
SWEET- study [1] was surprising. In previous placebo-con-
trolled trials of abciximab during coronary intervention,
GP IIb/IIIa blockade was found to reduce target vessel
revascularization (TVR) rates after ballon angioplasty in
patients without diabetes only in the EPIC trial [2], to
have no influence on TVR in patients without diabetes
after balloon angioplasty in EPILOG [3], or to reduce TVR
and angiographic restenosis in patients with diabetes only
after stenting in the EPISTENT [4,5] and ADMIRAL trials
[6]. Moreover in the ISAR-SMART-2 trial [7] and in the
CADILLAC-study [8] angiographic restenosis did not dif-
fer between patients treated with abciximab and placebo,
both after angioplasty and stenting.
The significant reduction in angiographic restenosis in
ISAR-SWEET [1] and CADILLAC [2] raises the question of
whether abciximab acts on clopidogrel-independent
mechanisms in suppressing neointimal hyperplasia. Two
potential examples of such mechanisms suggested include
anti-inflammatory effects on leukocyte Mac-I [9] and anti-
proliferative effects on vitronectin receptor on platelets
and smooth muscle cells [10]. Restenosis is essentially
characterized by migration and proliferation of smooth
muscle cells and extracellular matrix accumulation. In
human coronary restenotic lesions highly increased
migratory [11] and proliferative activity [12] have been
reported. There is now increasing evidence for a role of
inflammation in the development of restenosis. Our
group has demonstrated in a human coronary three-
dimensional model of leukocyte attack (3DLA-model)
that monocytes trigger a reactive proliferation of smooth
muscle cells [13]. Several authors have suggested that the
early rise in systemic markers of inflammation after angi-
oplasty can be diminished by abciximab [14,15].
The current study investigates the effect of abciximab on
expression of the intercellular adhesion molecule-1
(ICAM-1), migration, and proliferation in human vascu-
lar cells. The clinical relevance of the data is characterized
by the so-called SI/MPL-ratio [16], calculating the relation
between a significant inhibitory in vitro effect (SI) and the
maximal plasma level (MPL) of abciximab in vivo. A SI/
MPL-ratio < 1 characterizes an in vitro effect that can be
achieved after systemic administration of an agent in vivo,
a ratio > 1 indicates a mere local high dose option.
Methods
Cell culture
Endothelial cells from human umbilical veins (HUVEC)
were isolated after vaginal delivery by enzymatic disaggre-
gation with collagenase/dispase as described previously
[17]. Endothelial cells from human coronary arteries
(HCAEC) were purchased at Cambrex Bio- products
(Vervier, B). Cells were cultured in Endothelium Growth
Medium (Cambrex Bioproducts) and identified by the
typical "cobble stone" growth pattern and positive reac-
tion against von Willebrand factor (Dakopatts, Hamburg,
D). Smooth muscle cells from the human coronary media
(HCMSMC) were purchased at Cambrex Bioproducts.
HCMSMC were grown in Smooth Muscle Cell Growth
Medium (Cambrex Bioproducts). For identification of
HCMSMC antibodies against smooth muscle α-actin
(Sigma, Taufkirchen, D) were used.
Abciximab
Abciximab: Reopro®, Lilly, Bad Homburg, D, 0.0002 – 20
μg/mL, dilution: aqua ad inject., MPL: 0.175 μg/mL [18].
Flow cytometry
For flow cytometry analysis of the expression of ICAM-1
in HUVEC, HCAEC, and HCMSMC, 5 × 104 cells were
seeded into 6-well dishes. Abciximab (0.0002, 0.002,
0.02, 0.2, 2.0, and 20.0 μg/ml) was added to the cultures
for a period of 18 h. During the last 6 h of abciximab incu-
bation, the expression of adhesion molecules was stimu-
lated by adding of TNF-α (20 ng/ml).
After abciximab/TNF-α treatment, cells were washed twice
with phosphate-buffered saline (pH 7.2) containing 1%
fetal calf serum at 4°C. Cells were resuspended in 100 μl
of a FITC-conjugated monoclonal antibody directed
against ICAM-1 (clone 84H10, Dianova Immunotech;
final concentration 10 μg/ml) and incubated for 20 min
at 4°C. A total of 1 × 104 cells (100% gated) were analyzed
immediately with a flowcytometer (BDFACsCalibur, Bec-
ton Dickinson, Heidelberg, D). Controls were carried out
with IgG-FITC and actinomycin.
Migration studies
Migration of HCMSMC was measured by a 24 well color-
imetric assay (Chemicon, Hampshire, UK), based on the
Boyden Chamber principle. HCMSMC were incubated
with SmBM medium supplemented with 1% fetal calf
serum (fcs) for a period of 48 h. Thereafter HCMSMC
were seeded on the upper side of the polycarbonate mem-
brane (pore size 8 μm) of the Boyden Chamber. Migration
of HCMSMC was stimulated by filling the lower chamber
of the kit with SmBM medium supplemented with 10%
fcs. Abciximab was added to the medium of the lower
chamber in concentrations of 0.0002, 0.002, 0.02, 0.2,
2.0, and 20.0 μg/mL. After 24 h of incubation HCMSMC
were removed from the upper side of the membrane.
Thereafter the membranes were stained for 20', airdryed,
and incubated with extraction buffer for 15'. The opitical
density of 100 μl of this solution was measured at 560
nm, SmBM medium supplemented with 10% fcs was used
as control (100%).BMC Cardiovascular Disorders 2006, 6:14 http://www.biomedcentral.com/1471-2261/6/14
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Proliferation studies
HUVEC, HCAEC, and HCMSMC in passages 3–5 were
seeded in a density of 3 – 5 × 103 cells × cm-2 in 6-well
dishes. 24 h after seeding the corresponding culture
medium was renewed and the number of adherent cells
was analyzed in a cell counter (CASY TTC, Schärfe System,
Reutlingen, D). Subsequently abciximab was added in
concentrations of 0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0
μg/mL for another five days. Culture medium and abcixi-
mab were renewed at day three after seeding. Cell number
after incubation with abciximab was calculated as relative
cell number in comparison to untreated controls with the
concerning solvent. Taking into account that not all cells
could be successfully cultured, cell numbers of untreated
controls were calculated as:
Total cell number at day 6 – cell number attached at day 1
after seeding = 100%.
Vitality of cells
In a luminescent cell viability assay (CellTiter-GloTM,
Promega, Mannheim, D) the effects of abciximab in con-
centrations of 0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/
ml (HUVEC, HCAEC, and HCMSMC) were analyzed for a
period of five days in 96 well dishes (Nunc, Roskilde, DK).
Luminescence of luciferase reaction as a marker of cell via-
bility was measured in a CentroLB960 (Berthold, Tech-
nologies, Bad Wildbad, D).
SI/MPL-Ratio
As recently reported by our group [16] a SI/MPL-ratio was
calculated in order to characterize the clinical impact of
positive in vitro data:
Concentration with a significant inhibition in vitro (SI)
Maximal systemic plasma level (MPL)
Statistical analysis
Data of migration and proliferation studies are presented
as mean ± S.D. Statistical significance of differences
between controls and drug-treated cells was determined
by paired Student's t-test. Statistical significance was
accepted for P < 0.05.
Results
Identification of cells
Monocultures of HUVEC and HCAEC were identified by
positive reaction with antibodies directed against von Wil-
lebrand factor and by the typical "cobblestone" growth
pattern in culture. Monocultures of HCMSMC exhibited
the "hill and valley" growth pattern and reacted positively
with antibodies against smooth muscle α-actin.
Effects of abciximab on expression of ICAM-1
The effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0,
and 20.0 μg/ml) on the TNF-α induced expression of
ICAM-1 are demonstrated in Figure 1. In HUVEC,
HCAEC, and HCMSMC no significant effects of abcixi-
mab were detected.
Effects of abciximab on cell migration
The effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0,
and 20.0 μg/ml) on migration of HCMSMC are shown in
Figure 2 and Table 1. After a migration period of 24 h a
stimulatory effect was detected after incubation of
HCMSMC with abciximab in concentration of 0.0002 μg/
ml – 2 μg/ml, no effect was found after incubation with
the maximal concentration of 20 μg/ml.
After incubation of HCMSMC with abciximab in concen-
trations of 0.0002, 0.002, and 0.02 μg/ml cell migration
was increased by 36.29% (p < 0.05), 36.68% (p < 0.001),
and 32.43% (n.s.). The stimulatory effect decreased after
incubation with 0.2 and 2 μg/ml of abciximab, cell migra-
tion was increased by 20.37% (p < 0.05) and 10.81%
(n.s.), respectively. After incubation of HCMSMC with the
maximal concentration of 20 μg/ml of abciximab no
effect on cell migration was detected.
Effects of abciximab on cell proliferation
The effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0,
and 20.0 μg/ml) on proliferation of HUVEC, HCAEC, and
HCMSMC are demonstrated in Figure 3 and Table 2. After
incubation with high concentrations of abciximab small
but significant inhibitory effects were detected.
In HUVEC small but significant inhibitory effects were
detected after incubation with abciximax in concentra-
tions of 0.02 μg/ml and 2 μg/ml, cell proliferation was
decreased to 90.19% (p = 0.01; SI/MPL-ratio: 0.11) and
83.47% (p < 0.01; SI/MPL-ratio: 11.4), respectively. No
significant inhibitory effects were found after incubation
of HUVEC with abciximab in concentrations of 0.0002
μg/ml, 0.002 μg/ml, 0.2 μg/ml, and 20 μg/ml, cell prolif-
eration was decreased to 96.41%, 93.77%, 90.37%, and
79.34%.
In HCAEC no significant inhibitory effects were detected
after incubation with abciximab in concentrations of
0.002 μg/ml, 0.002 μg/ml, 0.02 μg/ml, and 0.2 μg/ml, cell
proliferation was decreased to 88.50%, 87.17%, 88.35%,
and 85.09%. Small but significant inhibitory effects were
found after incubation of HCAEC with abciximab in con-
centrations of 2 μg/ml and 20 μg/ml, cell proliferation
was decreased to 91.87% (p < 0.05; SI/MPL-ratio: 11.4)
and 87.70% (p < 0.01; SI/MPL-ratio: 114).BMC Cardiovascular Disorders 2006, 6:14 http://www.biomedcentral.com/1471-2261/6/14
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After incubation of HCMSMC with abciximab in concen-
trations of 0.002 μg/ml, 0.002 μg/ml, 0.02 μg/ml, and 0.2
μg/ml no significant inhibitory effects were detected in
comparison to untreated controls, cell proliferation was
100.18%, 91.86%, 90.85%, and 86.90%. Small but signif-
icant inhibitory effects were found after incubation of
HCMSMC with abciximab in concentrations of 2 μg/ml
and 20 μg/ml, cell proliferation was decreased to 85.79%
(p < 0.05; SI/MPL-ratio: 11.4) and 81.09% (p < 0.05; SI/
MPL-ratio: 114).
Effects of abciximab on cell vitality
Cell vitality of HUVEC, HCAEC, and HCMSMC was ana-
lyzed after incubation with abciximab in concentrations
of 0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml. Cell vital-
ity was slightly increased in HUVEC and HCAEC and
slightly decreased in HCMSMC. Statistical significance of
the differences in comparison to untreated controls was
not achieved.
In HUVEC cell vitality was slightly increased after incuba-
tion with abciximab in concentrations of 0.0002, 0.002,
0.02, 0.2, 2.0, and 20.0 μg/ml. Cell vitality in comparison
to untreated controls was 106.83%, 117.57%, 112.30%,
108.43%, 111.31%, and 111.36%.
In HCAEC a similar result was detected, cell vitality was
slightly increased. In comparison to untreated controls
cell vitality was 113.38%, 117.24%, 105.99%, 112.68%,
109.15%, and 106.70%.
Expression of ICAM-1 Figure 1
Expression of ICAM-1. The effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on TNF-α induced expression of 
intercellular adhesion molecule 1 (ICAM-1) in HUVEC, HCAEC and HCMSMC after 18 h (cytoflow data): Controls (thin grey 
line), non stimulated basic expression of ICAM-1 (grey line), expression of ICAM-1 after stimulation with TNF-α (thick grey 
line), expression of ICAM-1 after stimulation with TNF-α plus abciximab (black line).BMC Cardiovascular Disorders 2006, 6:14 http://www.biomedcentral.com/1471-2261/6/14
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In HCMSMC a slight decrease of cell vitality was detected
after incubation with abciximab in concentrations of
0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml. Cell vitality
in comparison to untreated controls was 86.94%,
86.51%, 96.64%, 82.50%, 97.49%, and 89.82%.
Discussion
The present in vitro study investigated the effects of abcix-
imab on key pattern of human coronary restenosis. Three
basic conclusions were determined. First, abciximab
(0.0002 μg/ml – 20 μg/ml) had no effect on expression of
ICAM-1 in HUVEC, HCAEC, and HCMSMC. Second,
abciximab (0.0002 μg/ml – 2 μg/ml) stimulated migra-
tion of HCMSMC. Third, high concentrations of abcixi-
mab had a small but significant antiproliferative effect in
HUVEC, HCAEC, and HCMSMC, SI/MPL-ratio's > 1 indi-
cate that these effects can't be achieved after systemic infu-
sion.
During the last decade, intensive efforts have been made
to evaluate the role of the platelet glycoprotein (GP) IIb/
IIIa complex in platelet-mediated thrombus formation.
Acitivation of the GP IIb/IIIa platelet-surface integrin by
endogenous agonists (e.g. thrombin, adenosine diphos-
phate or ADP, and collagen) results in binding of adhesive
proteins such as fibrinogen and von Willebrand factor,
thus mediating platelet aggregation [20]. Significant
efforts have been made to design potent antagonists of
this "final common pathway" of platelet aggregation to be
used as novel therapeutic strategies to treat acute coronary
syndromes. Antagonists directed against the GP IIb/IIIa
Proliferation Figure 3
Proliferation. Effects of abciximab (0.0002, 0.002, 0.02, 0.2, 
2.0, and 20.0 μg/ml) on proliferation of HUVEC (A), HCAEC 
(B), and HCMSMC (C) in comparison to untreated controls 
at day six after seeding, C = control, (p < 0.05 = *; p < 0.01 = 
**; p < 0.001 = ***; paired Student's t-test).
Table 1: Migration. Effects of abciximab (0.0002, 0.002, 0.02, 0.2, 
2.0, and 20.0 μg/ml) on migration of HCMSMC (48 h) in 
comparison to untreated controls, C = controls
Migration (%) HCMSMC
C1 0 0
0,0002 μg/ml Abciximab 136,29 ± 8,66
0,002 μg/ml Abciximab 136,68 ± 2,97
0,02 μg/ml Abciximab 132,43 ± 10,01
0,2 μg/ml Abciximab 120,37 ± 6,01
2 μg/ml Abciximab 110,81 ± 10,0
20 μg/ml Abciximab 98,17 ± 13,23
Migration Figure 2
Migration. Effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, 
and 20.0 μg/ml) on migration of HCMSMC (48 h) in compar-
ison to untreated controls. C = controls, bar 100 μm. (p < 
0.05 = *; p < 0.01 = **; p < 0.001 = ***; paired Student's t-
test).BMC Cardiovascular Disorders 2006, 6:14 http://www.biomedcentral.com/1471-2261/6/14
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receptor represent a family of antiplatelet drugs that are
used clinically for the prevention of pathological throm-
boses [21]. Abciximab, a monoclonal antibody Fab frag-
ment, was the first approved agent in this class of drugs
[22]. Although a decade ago abciximab has been shown to
prevent acute ischemic complications from percutaneous
transluminal coronary angioplasty (PTCA) and atherec-
tomy [23], recent data of Kastrati et al. [24] in the ISAR-
REACT-study did not find any clinically measurably ben-
efits during the first 30 days in low to intermediate percu-
taneous coronary interventions after pretreatment with a
high loading dose of clopidogrel and abciximab in com-
parison to clopidogrel alone.
Charo et al. [25] were the first to demonstrate that platelet
GP IIb/IIIa-like proteins mediate the adherence of
HUVEC to specific adhesive proteins. Yasukawa et al. [26]
demonstrated that ICAM-1 is expressed early and
intensely in rat carotid arteries after balloon injury and
that monoclonal antibodies to ICAM-1 significantly sup-
press restenosis. ICAM-1 is a highly glycosylated cell sur-
face protein of 95 kD that is expressed on variable levels
on endothelial cells, smooth muscle cells, and circulating
leukocytes [27]. In cultured human coronary endothelial
and smooth muscle cells expression of ICAM-1 is highly
upregulated by TNF-α [28]. Inoue et al. [29] demonstrated
that serum levels of ICAM-1 and P-selectin were signifi-
cantly increased immediately after angioplasty in human
coronary sinus blood samples. Therefore inhibition of
ICAM-1 has been targeted as a strategy to inhibit resteno-
sis [30].
The current study demonstrates that abciximab in concen-
trations ranging from 0.0002 μg/ml – 20 μg/ml has no
effect on expression of ICAM-1 in HUVEC, HCAEC, and
HCMSMC. The data are in accordance with a recent report
of Massberg et al. [31] that abciximab infusion did not sig-
nificantly affect platelet-induced endothelial cell expres-
sion of ICAM-1 in 20 patients undergoing coronary
stenting. On the other hand Schwarz et al. [32] reported
that abciximab inhibited significantly adhesion of a
monocytic cell line to immobilized ICAM-1 in vitro.
Migration [11] and proliferation [12] of human coronary
smooth muscle cells is significantly increased in speci-
mens derived from restenosing lesions. Systemic treat-
ment with αvβ3 antagonists such as abciximab reduce
neointima formation after injury of rat carotid [33], rabbit
carotid [34], hamster carotid [35], pig coronary [36], pig
carotid and femoral [37] and rabbit iliac [38,39] arteries.
The mechanisms that caused the anti-restenotic effect in
these studies are difficult to identify. It has been reported
by Stouffer et al. [40] that vascular cell β3 integrin expres-
sion is increased after injury and that abciximab binds to
cultured SMC with high affinity. Moreover, the group of
Stouffer et al. [40] demonstrated that β3 activation is
important for alpha-thrombin induced cell proliferation.
In the present study a stimulatory effect on cell migration
was detected after incubation of HCMSMC with abcixi-
mab in concentrations of 0.0002 – 2 μg/mL, statistical sig-
nificance was achieved after incubation with abciximab in
concentrations of 0.0002 μg/ml, 0.002 μg/ml, and 0.2 μg/
ml. Neither stimulatory nor inhibitory effects on cell
migration were detected after incubation of HCMSMC
with abciximab in a concentration of 20 μg/ml. In the
applied migration model merely direct effects on cell
migration can be studied. Indirect effects that block
thrombin-induced migration cannot be considered due to
the fact that thrombin is not present in the system [41].
Due to the fact that a concentration of abciximab of 0,175
μg/mL is considered as maximal plasma level (MPL) after
systemic infusion [18], the present data demonstrate that
direct anti-migratory effects of abciximab may not con-
tribute to the anti-restenotic effects described in experi-
mental [33-39] and clinical [1,2,5-7] studies. These data
are in contrast to a report of Blindt et al. [42,43] describ-
ing a significant anti-migratory effect after administration
of abciximab in a concentration of 33 μg/mL. Cell specific
differences can be excluded because the group of Blindt et
Table 2: Proliferation. Effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on proliferation of HUVEC, HCAEC, and 
HCMSMC in comparison to untreated controls at day six after seeding, C = control, (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***; paired 
Student's t-test)
Proliferation (%) HUVEC HCAEC HCMSMC
C 100 ± 0 100 ± 0 100 ± 0
0,0002 μg/ml Abciximab 96,41 ± 6,16 88,5 ± 7,2 100,18 ± 17,10
0,002 μg/ml Abciximab 93,77 ± 3,88 87,17 ± 9,02 91,86 ± 15,64
0,02 μg/ml Abciximab 90,19 ± 1,77 88,35 ± 3,04 90,85 ± 11,33
0,2 μg/ml Abciximab 90,37 ± 7,38 85,09 ± 8,27 86,90 ± 8,43
2 μg/ml Abciximab 83,47 ± 2,51 91,87 ± 3,25 85,79 ± 8,56
20 μg/ ml Abciximab 79,34 ± 9,16 87,70 ± 6,01 81,09 ± 7,59BMC Cardiovascular Disorders 2006, 6:14 http://www.biomedcentral.com/1471-2261/6/14
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al. used human coronary smooth muscle cells as well. The
contrasting results may be partially explained by the fact
that Blindt et al. administered abciximab 24 h before and
during migration. In the current study, as in patients,
abciximab was administered merely during and not
before and during the migration process.
In the present study a small but significant antiprolifera-
tive effect was detected after adding abciximab in concen-
trations of 2 μg/mL and 20 μg/mL, resulting in SI/MPL-
ratio's beyond 1. The effect of abciximab on cell prolifera-
tion in human coronary vascular cells has already been
studied by the group of Blindt et al. [42,43]. Both modest
antiproliferative effects [42] and no antiproliferative effect
have been reported [43]. The small but significant anti-
proliferative in vitro effect of abciximab in the current
study was achieved with SI/MPL-ratio's of 11.4 and 114,
indicating that the corresponding drug concentrations
were 11.4- and 114-times, respectively, beyond the MPL
of 0,175 μg/mL. Equally as described for direct anti-migra-
tory effects, a contribution of direct antiproliferative
effects of abciximab for the experimental [33-39] and clin-
ical [1,2,5-7] anti-restenotic effects can be excluded. The
small but significant antiproliferative effect of abciximab
however might be used in local high dose application sys-
tems such as coated stents [44].
Limitations of the study
The present study investigates direct effects of abciximab
on ICAM-1 expression, migration and proliferation. The
primary target for abciximab, however, is the platelet
GPIIb/IIIa receptor, which is blocked by the antibody
thereby preventing complex formation between the plate-
let and fibrinogen. Inhibition of platelet aggregation
results in the release of multiple platelet derived growth
factors capable of affecting smooth muscle proliferation
and expression of adhesion molecules. Thus, the absence
of platelets in the in vitro system, as well as the absence of
other cellular components and immunological reactions
initiated by increased platelet activity are not replicated in
the present experimental protocol.
Conclusion
Although an effect of abciximab on expression of ICAM-1
in HUVEC, HCAEC and HCMSMC was excluded in the
present study, an effect of abciximab on monocytes is pos-
sible and should be confirmed in further studies. One of
the possible models for the evaluation of these mecha-
nisms might be the 3DLA-model reported earlier by our
group (13).
Equally as described for direct anti-migratory effects, a
contribution of direct antiproliferative effects of abcixi-
mab for the experimental and clinical anti-restenotic
effects can be excluded. The small but significant antipro-
liferative effect of abciximab (SI/MPL-ratio > 1) indicates
a local high dose option that might be of clinical use in
coated stents (44).
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